Traders’ Favorite: National Bank of Greece, EMC Corporation, BioCryst Pharmaceuticals
NEW YORK, April 08, 2013 -Bestdarnpennystocks.com, one of the leaders in providing investment alerts on U.S. stocks are announcing Investment Highlights on National Bank of Greece, EMC Corporation, BioCryst Pharmaceuticals.
National Bank of Greece (ADR)(NYSE:NBG) shares fell 12.36% to $0.631. The company, on Mar. 19, announced the initiation of the merger process with Eurobank Ergasias SA. The merger will be effected through the absorption of Eurobank Ergasias SA by National Bank of Greece SA, by consolidating the assets and liabilities of the two merging banks, in accordance with the combined provisions of article 16 of l.
Is NBG a Buy After Today’s Tumble? Find Out Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=NBG (OR Just copy and paste the link)
EMC Corporation(NYSE:EMC) shares fell 0.30% to $23.01. Oppenheimer analyst Ittai Kidron reiterated an Outperform rating on EMC Corporation on April 3, but lowered the price target from $30.00 to $28.00.
How Should investors Trade EMC Now? Get Free Trend Analysis Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=EMC (OR Just copy and paste the link)
Additionally, the company, on Mar. 21, announced that Mediaprint, the largest newspaper and magazine publisher in Austria, has transformed its IT infrastructure with EMC(®) VNX(®) unified storage, EMC VPLEX(®) Metro virtual storage and VMware virtualization solutions. The EMC and VMware solutions have enabled Mediaprint to increase application performance by 300%, achieve five-nines availability for critical publishing, editorial and production systems, as well as accelerate virtualization of its IT infrastructure.
Research Triangle Park pharma BioCryst Pharmaceuticals, Inc.(NASDAQ:BCRX) has received a comment letter from the U.S. Food and Drug Administration indicating how a New Drug Application (NDA) could be filed for the stalled government-funded flu treatment.
But BioCryst has also received a stop-work notification from the U.S. Department of Health and Human Services which funds the drug development, asking the company to cease work on peramivir.
Is BCRX a Strong Buy After Today’s Solid Gain? Get Free Report Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=BCRX (OR Just copy and paste the link)
Certain activities related to the FDA meeting will still happen, and the Biomedical Advanced Research and Development Authority (BARDA) will continue to fund certain activities.
CEO Jon Stonehouse had this to say: “Our ultimate objective is the approval of peramivir as an intravenous treatment option that could benefit patients in the United States. The Stop-Work Order is understandable, as it focuses the scope of reimbursable activities to those that are essential and supportive to continuing regulatory communications, with the objective of preparing an NDA submission.”
If the meetings are successful, he hopes to file an NDA for peramivir as soon as possible.
Shares of BCRX soared over 14% to $1.94.
Johnson & Johnson (NYSE:JNJ) shares decreased 1.47% to $80.83. The company on Mar. 22 said it may soon cause frown lines at Allergan Inc, maker of Botox. J&J expects to seek U.S. approval next year for an anti-wrinkle drug that could break Botox's near monopoly, an 85 percent market share. The J&J product could be available in the United States in 2015 and overseas a few years later, the company said.
Get latest News & Updates On JNJ here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=JNJ
(OR Just copy and paste the link)
About bestdarnpennystocks.com
bestdarnpennystocks.com’s team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.
Disclaimer
The assembled information disseminated by bestdarnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. bestdarnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in bestdarnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.
Contacts:
bestdarnpennystocks.com
1419 Westwood Blvd Los Angeles, CA
90024-4911
staff@bestdarnpennystocks.com